Effects of Tranexamic Acid on Blood Loss and Transfusion Requirement Following Hip Fracture
| Status: | Recruiting |
|---|---|
| Conditions: | Orthopedic |
| Therapuetic Areas: | Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Contact: | Tiffany Morrison, MS, CCRP |
| Email: | tiffany.morrison@rothmaninstitute.com |
| Phone: | 267-339-7818 |
Tranexamic acid (TA) inhibits fibrinolysis by binding to lysine binding-sites of plasminogen
to fibrin. Fibrinolysis is stimulated by surgical trauma, and the administration of TA has
been shown effective in decreasing blood loss both intra-operatively and in the immediate
post-operative period in elective hip and knee arthroplasty patients. Both the timing and
dosing of TA has been investigated in these patients. Subsequent blood transfusion rate has
also been shown to decrease as result of TA administration. Despite the support for TA
utilization that exists in the arthroplasty literature, the data is scarce regarding its
administration during surgical treatment of hip fractures. This is patient population who is
at high risk for transfusion due to symptomatic post-operative anemia. This study aims to
investigate whether TA's advantageous effects in the arthroplasty patient population can be
extrapolated to the more unstable, heterogeneous hip fracture patient population. If the
study is able to show a difference in blood loss and transfusion requirement, the long term
implications of this with regards to cost and mortality can be significant.
to fibrin. Fibrinolysis is stimulated by surgical trauma, and the administration of TA has
been shown effective in decreasing blood loss both intra-operatively and in the immediate
post-operative period in elective hip and knee arthroplasty patients. Both the timing and
dosing of TA has been investigated in these patients. Subsequent blood transfusion rate has
also been shown to decrease as result of TA administration. Despite the support for TA
utilization that exists in the arthroplasty literature, the data is scarce regarding its
administration during surgical treatment of hip fractures. This is patient population who is
at high risk for transfusion due to symptomatic post-operative anemia. This study aims to
investigate whether TA's advantageous effects in the arthroplasty patient population can be
extrapolated to the more unstable, heterogeneous hip fracture patient population. If the
study is able to show a difference in blood loss and transfusion requirement, the long term
implications of this with regards to cost and mortality can be significant.
Inclusion Criteria:
Patients admitted to Bryn Mawr Hospital with fracture of the femoral neck,
intertrochanteric region, or subtrochanteric region of the femur will be considered for
the study.
Exclusion Criteria:
Exclusion criteria include
- age under 18
- allergy to TA
- known current or history of venous thromboembolism (VTE)
- history of known coagulopathy or bleeding disorder
- current subarachnoid hemorrhage
- previous history of seizures
- current use of estrogen/progesterone therapy
- renal failure defined as creatinine clearance less than 30 ml/min4
- multiple fractures
- pregnant or breastfeeding women
- planned nonoperative management of the fracture
We found this trial at
1
site
Bryn Mawr Hospital Bryn Mawr Hospital, a nationally recognized community teaching hospital, is conveniently located...
Click here to add this to my saved trials
